REPORT BY THE DIRECTOR-GENERAL

FINANCIAL, ADMINISTRATIVE, AND PROGRAMME AND BUDGET IMPLICATIONS OF THE PROPOSAL FOR AN UNDERSTANDING REGARDING THE AEROSOLISED USE OF CENTRAL NERVOUS SYSTEM-ACTING CHEMICALS FOR LAW ENFORCEMENT PURPOSES

1. A revised proposal entitled “Understanding Regarding the Aerosolised Use of Central Nervous System-Acting Chemicals for Law Enforcement Purposes”, co-sponsored by Albania, Australia, Austria, Bulgaria, Canada, Colombia, Croatia, Cyprus, the Czech Republic, Estonia, Finland, Greece, Japan, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, the Republic of Korea, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, and the United States of America, was issued and circulated to States Parties (EC-92/DEC/CRP.9/Rev.4, dated 5 October 2020).

2. On behalf of the co-sponsors, Australia, Switzerland, and the United States of America presented, via diplomatic note (S/1799/2019, dated 4 October 2019), the proposal to the Executive Council (hereinafter “the Council”) for its consideration under item 17 (Any other business) of the agenda of its Ninety-Second Session.

3. At the request of the co-sponsors, in accordance with Rule 34 of the Rules of Procedure of the Council, the Director-General herewith reports on the financial, administrative, and programme and budget implications of the revised proposal.

4. In considering the implications of the revised proposal, the Technical Secretariat estimates that any additional requirements associated with the adoption of the revised proposal could be met within existing resources.

5. It should be noted that the budgetary impact figure provided in the table below represents the total estimated cost associated with the adoption of the draft revised decision/proposal.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Budgetary Impact (in millions of euros)</td>
<td>Nil</td>
</tr>
</tbody>
</table>

---